Evidence map›Paper›PMID 41301404›Full record

ArticleBiomolecules2025

Fingolimod Improves Anxiety-like Behavior and Modulates Sphingosine-1-Phosphate Receptors Gene Expression in a Diabetic Mouse Model.

Przemysław Leonard Wencel, Kamilla Blecharz-Klin, Agnieszka Piechal, Justyna Pyrzanowska, Dagmara Mirowska-Guzel, Robert Piotr Strosznajder

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Przemysław Leonard WencelLaboratory of Preclinical Research and Environmental Agents, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego St., 02-106 Warsaw, Poland.
Kamilla Blecharz-KlinDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT, Medical University of Warsaw, 1B Banacha St., 02-097 Warsaw, Poland.ORCID 0000-0002-0990-3017
Agnieszka PiechalDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT, Medical University of Warsaw, 1B Banacha St., 02-097 Warsaw, Poland.ORCID 0000-0002-0335-3288
Justyna PyrzanowskaDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT, Medical University of Warsaw, 1B Banacha St., 02-097 Warsaw, Poland.ORCID 0000-0002-0776-8077
Dagmara Mirowska-GuzelDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT, Medical University of Warsaw, 1B Banacha St., 02-097 Warsaw, Poland.ORCID 0000-0001-6294-3256
Robert Piotr StrosznajderLaboratory of Preclinical Research and Environmental Agents, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego St., 02-106 Warsaw, Poland.

Funding

MMRI statutory budget theme 7National Science Centre, Poland (NCN) 2018/29/N/NZ4/00616
6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2DM) is a rapidly expanding worldwide health issue associated with impairments in memory and executive functions. The bioactive sphingolipid sphingosine-1-phosphate (S1P) regulates cell death/survival and the inflammatory response by acting on S1P receptors (S1PRs). Unfortunately, the role of S1PRs signaling in the T2DM brain remains elusive.

methodsThe effect of fingolimod (FTY720, S1PRs modulator) on the behavior and expression profile of genes encoding S1PRs, sphingosine kinases (SPHK1 and 2), glucose transporters, proteins engaged in insulin signaling, sirtuin 1 (SIRT1), and proinflammatory cytokines in the brain cortex and hippocampus of diabetic mice was examined.

resultsWe observed a significant reduction in

conclusionsResults indicate an important role of S1PR modulation in T2DM. Moreover, fingolimod affected mRNA levels of proteins engaged in glucose metabolism/insulin signaling and improved the behavior of diabetic mice.

Indexed as

AnxietyDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Fingolimod HydrochlorideSphingosine-1-Phosphate ReceptorsAnimalsBehavior, AnimalDisease Models, AnimalGene Expression RegulationHippocampusMaleMiceMice, Inbred C57BLSignal TransductionFingolimod HydrochlorideSphingosine-1-Phosphate Receptorsbehaviorbrain cortexcytokinesdiabetesfingolimodFTY720hippocampusinflammationsphingosine-1-phosphatesphingosine kinases

Identifiers

PMID41301404
PMCPMC12650383

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.